Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: Risk of Serious and Fatal Outcomes
20 August 2026 The South African Health Products Regulatory Authority (SAHPRA) wishes to remind healthcare professionals of the risk of angioedema during treatment with angiotensin-converting enzyme (ACE) inhibitors (e.g. captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, trandolapril). Healthcare professionals are reminded that ACE inhibitor treatment should... The post Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: Risk of Serious and Fatal Outcomes appeared first on SAHPRA.
Read the original at the source: https://www.sahpra.org.za/angiotensin-converting-enzyme-inhibitor-induced-angioedema-risk-of-serious-and-fatal-outcomes/
Officially imported this from SAHPRA’s own source. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- SAHPRA — imported from official source
- Official source
- https://www.sahpra.org.za/feed/ RSS
- Imported
- October 03, 2026 20:35
- Versions
- 1 recorded
- Identity
https://www.sahpra.org.za/?p=20245